Modified cytomegalovirus proteins and stabilized complexes
US-2024383949-A1 · Nov 21, 2024 · US
Ex vivo method for producing a preparation containing CD4+ T cells specific for EBV structural antigens
US9028840B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9028840-B2 |
| Application number | US-74447408-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 27, 2008 |
| Priority date | Nov 27, 2007 |
| Publication date | May 12, 2015 |
| Grant date | May 12, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention discloses an ex vivo method for producing a preparation containing CD4+ T cells specific for EBV structural antigens for use in the prophylaxis and treatment of patients with a reduced T cell activity in order to prevent or treat growth of EBV infected B cells.
First claim
Opening claim text (preview).
The invention claimed is: 1. An ex vivo method for producing a preparation containing CD4+ T cells specific for EBV structural antigens, the method comprising incubating B cells with preparations of Epstein-Barr virus-like particles (EB-VLPs) containing EBV structural antigens and devoid of transforming EBV DNA for a time period sufficient to generate a preparation containing B cells presenting EBV structural antigens, wherein said B cells are primary B cells; admixing said B ce…
Assignees
Inventors
Classifications
- A61K39/245Primary
Human Necessities · mapped topic
Human Necessities · mapped topic
Human Necessities · mapped topic
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9028840B2 cover?
- The present invention discloses an ex vivo method for producing a preparation containing CD4+ T cells specific for EBV structural antigens for use in the prophylaxis and treatment of patients with a reduced T cell activity in order to prevent or treat growth of EBV infected B cells.
- Who is the assignee on this patent?
- Adhikary Dinesh, Behrends Uta, Mautner Josef, and 4 more
- What technology area does this patent fall under?
- Primary CPC classification A61K39/245. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue May 12 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).